Diese Seite wurde automatisch übersetzt und die Genauigkeit der Übersetzung wird nicht garantiert. Bitte wende dich an die englische Version für einen Quelltext.

Impact of Advanced Parkinson Therapies on Clinical Status: Deep Brain Stimulation and Foslevodopa/Foscarbidopa (IMPACT-PD)

11. November 2026 aktualisiert von: Medical University of Warsaw

The Impact of Selected Advanced Therapies on the Clinical Status of Patients With Parkinson's Disease.

The goal of this observational study is to learn how treatment with selected advanced therapies for Parkinson's disease affect disease motor symptoms, cognition, body weight, body composition and inflammatory biomarkers in people with advanced Parkinson's disease.

The main questions it aims to answer are:

  • How do clinical symptoms, cognitive function, body composition and blood biomarkers change during the first 12 months after starting the treatment?
  • Are there differences in outcomes between participants treated with DBS and those treated with foslevodopa/foscarbidopa infusion?

Participants will:

  • Undergo deep brain stimulation (DBS) or start continuous subcutaneous foslevodopa/foscarbidopa infusion as part of their routine clinical care.
  • Attend study visits over 12 months and complete assessments of motor and non-motor symptoms, cognition, gait and balance.
  • Provide blood samples and undergo magnetic resonance imaging (MRI) and body composition measurements.

Studienübersicht

Status

Rekrutierung

Bedingungen

Detaillierte Beschreibung

Parkinson's disease (PD) is a progressive neurodegenerative disorder characterized primarily by degeneration of dopaminergic neurons in the substantia nigra and accumulation of α-synuclein. In advanced stages, patients develop motor fluctuations, dyskinesias, and progressive disability despite optimized oral pharmacotherapy, leading to consideration of advanced treatment strategies.

This prospective observational cohort study aims to evaluate clinical, neuropsychological, biochemical, body composition and digital biomarker changes in patients with advanced PD undergoing two advanced therapies: deep brain stimulation (DBS) of the subthalamic nucleus and continuous subcutaneous infusion of foslevodopa/foscarbidopa.

The study will follow participants for 12 months after initiation of advanced therapy. Assessments will be performed at baseline (pre-treatment) and at predefined follow-up visits to evaluate longitudinal changes in motor and non-motor symptoms, cognitive performance, quality of life, gait and balance function, and body composition. Motor outcomes will be assessed using standardized clinical scales including the Movement Disorder Society Unified Parkinson's Disease Rating Scale (UPDRS), with particular emphasis on the motor subsection (Part III). Non-motor symptoms and health-related quality of life will be evaluated using validated questionnaires.

In addition to clinical assessments, the study includes multimodal measures to evaluate potential correlates of disease progression and treatment response. These include peripheral blood tests assessing inflammatory, metabolic, neuroendocrine, and nutritional parameters performed longitudinally during follow-up, as well as multiple assessments of body composition. Neuroimaging with MRI, including tractography, will be performed at baseline for structural characterization of participants. Digital wearable devices will be used intermittently to capture motor fluctuations and dyskinesias.

Studientyp

Beobachtungs

Einschreibung (Geschätzt)

92

Kontakte und Standorte

Dieser Abschnitt enthält die Kontaktdaten derjenigen, die die Studie durchführen, und Informationen darüber, wo diese Studie durchgeführt wird.

Studienkontakt

Studienorte

    • Masovian Voivodeship
      • Warsaw, Masovian Voivodeship, Polen, 03-242
        • Rekrutierung
        • Department of Neurology at Mazowiecki Bródnowski Hospital
        • Kontakt:

Teilnahmekriterien

Forscher suchen nach Personen, die einer bestimmten Beschreibung entsprechen, die als Auswahlkriterien bezeichnet werden. Einige Beispiele für diese Kriterien sind der allgemeine Gesundheitszustand einer Person oder frühere Behandlungen.

Zulassungskriterien

Studienberechtigtes Alter

40 Jahre bis 80 Jahre (Erwachsene, Älterer Erwachsener)

Akzeptiert gesunde Freiwillige

Nein

Studienberechtigte Geschlechter

Alle

Probenahmeverfahren

Nicht-Wahrscheinlichkeitsprobe

Studienpopulation

Participants will be recruited from patients with advanced Parkinson's disease receiving care at the Department of Neurology, Masovian Bródno Hospital in Warsaw, Poland, a referral center for movement disorders in the region. Recruitment will take place during hospital admissions as part of routine clinical care to assess eligibility for advanced therapies for Parkinson's disease.

Beschreibung

Inclusion Criteria:

- people with advanced PD, complicated by dyskinesias and fluctuations in motor status, qualified for one of the advanced therapies using the 5-2-1 criteria for PD: surgical treatment with DBS or treatment with subcutaneous infusions of foslevodopa and foscarbidopa.

Exclusion Criteria:

  • previous surgery of the central nervous system
  • concomitant neurological diseases
  • serious circulatory system disease or risk of stroke or heart attack
  • renal or hepatic failure
  • cancer
  • active chronic inflammatory autoimmune disease
  • contraindications to MRI examination (ferromagnetic metal elements in the body, claustrophobia, pregnancy) or measurement of body composition by bioimpedance method (pregnancy, epilepsy, pacemaker, cardioverter-defibrillator)

Studienplan

Dieser Abschnitt enthält Einzelheiten zum Studienplan, einschließlich des Studiendesigns und der Messung der Studieninhalte.

Wie ist die Studie aufgebaut?

Designdetails

  • Beobachtungsmodelle: COHORT
  • Zeitperspektiven: PROSPECTIVE

Kohorten und Interventionen

Gruppe / Kohorte
Deep Brain Stimulation (DBS)

Participants with advanced Parkinson's disease treated with bilateral subthalamic deep brain stimulation.

Subcutaneous foslevodopa/foscarbidopa infusion

Participants with advanced Parkinson's disease treated with continuous subcutaneous foslevodopa/foscarbidopa infusion.

Was misst die Studie?

Primäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Change in UPDRS Part III (Motor Examination) score
Zeitfenster: Baseline and 12 months

Change in motor function assessed using Part III of the MDS-UPDRS. Part III is a clinician-rated motor examination assessing features including bradykinesia, rigidity, tremor, gait, posture, and postural stability. The score ranges from 0 to 132 points, with higher scores indicating greater motor impairment.

Unit of Measure: Points on a scale.

Baseline and 12 months

Sekundäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Change in UPDRS Part I (Non-Motor Aspects of Experiences of Daily Living) score
Zeitfenster: Baseline, 3, 6, 9, and 12 months

Change in non-motor aspects of daily living assessed using Part I of the Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS). Part I evaluates non-motor symptoms including cognitive impairment, mood, sleep, pain, urinary symptoms, constipation, fatigue, and other non-motor manifestations. The score ranges from 0 to 52 points , with higher scores indicating greater severity of non-motor symptoms and greater impairment.

Unit of Measure: Points on a scale.

Baseline, 3, 6, 9, and 12 months
Change in UPDRS Part II (Motor Aspects of Experiences of Daily Living) score
Zeitfenster: Baseline, 3, 6, 9, and 12 months

Change in motor aspects of daily living assessed using Part II of the MDS-UPDRS. Part II evaluates the impact of motor symptoms on activities of daily living, including speech, eating, dressing, hygiene, handwriting, walking, and mobility. The score ranges from 0 to 52 points, with higher scores indicating greater motor-related disability.

Unit of Measure: Points on a scale.

Baseline, 3, 6, 9, and 12 months
Change in UPDRS Part IV (Motor Complications) score
Zeitfenster: Baseline, 3, 6, 9, and 12 months

Change in motor complications assessed using Part IV of the MDS-UPDRS. Part IV evaluates motor fluctuations and dyskinesias associated with Parkinson's disease treatment. The score ranges from 0 to 24 points, with higher scores indicating more severe motor complications.

Unit of Measure: Points on a scale.

Baseline, 3, 6, 9, and 12 months
Change in Montreal Cognitive Assessment (MoCA) score
Zeitfenster: Baseline and 12 months

Change in global cognitive performance assessed using the Montreal Cognitive Assessment (MoCA). The MoCA assesses several cognitive domains, including visuospatial and executive functions, naming, attention, language, abstraction, delayed recall, and orientation. The total score ranges from 0 to 30 points , with higher scores indicating better cognitive performance.

Unit of Measure: Points on a scale.

Baseline and 12 months
Change in Parkinson's Disease Questionnaire-39 (PDQ-39) score
Zeitfenster: Baseline, 3, 6, 9, and 12 months.

Change in health-related quality of life assessed using the Parkinson's Disease Questionnaire-39 (PDQ-39). The PDQ-39 consists of 39 items across eight domains. The Summary Index is calculated as the mean of the eight domain scores and ranges from 0 to 100, with higher scores indicating poorer health-related quality of life. Unit of Measure: Points on a scale.

Baseline, 3, 6, 9, and 12 months.
Change in Non-Motor Symptoms Scale (NMSS) score
Zeitfenster: Baseline, 3, 6, 9, and 12 months.

Change in non-motor symptoms assessed using the Non-Motor Symptoms Scale (NMSS). The scale consists of 30 items across nine domains. Each item is scored based on symptom severity (0-3) and frequency (1-4), with the scores multiplied. The total score ranges from 0 to 360, with higher scores indicating more severe non-motor symptoms.

Unit of Measure: Points on a scale.

Baseline, 3, 6, 9, and 12 months.
Change in Gastrointestinal Dysfunction Scale for Parkinson's Disease (GIDS-PD) score
Zeitfenster: Baseline, 3, 6, 9, and 12 months.

Change in gastrointestinal dysfunction assessed using the Gastrointestinal Dysfunction Scale for Parkinson's Disease (GIDS-PD). The total score ranges from 1 to 108, with higher scores indicating more severe gastrointestinal dysfunction.

Unit of Measure: Points on a scale.

Baseline, 3, 6, 9, and 12 months.
Change in Epworth Sleepiness Scale (ESS) score
Zeitfenster: Baseline, 3, 6, 9, and 12 months.

Change in daytime sleepiness assessed using the Epworth Sleepiness Scale (ESS). The scale consists of eight items, each scored from 0 to 3. The total score ranges from 0 to 24, with higher scores indicating greater daytime sleepiness.

Unit of Measure: Points on a scale.

Baseline, 3, 6, 9, and 12 months.
Change in Parkinson's Disease Sleep Scale (PDSS) score
Zeitfenster: Baseline, 3, 6, 9, and 12 months.

Change in sleep disturbances associated with Parkinson's disease assessed using the Parkinson's Disease Sleep Scale (PDSS). The total score ranges from 0 to 150, with higher scores indicating better sleep quality and fewer sleep disturbances. Unit of Measure: Points on a scale.

Baseline, 3, 6, 9, and 12 months.
Change in Freezing of Gait Questionnaire (FOG-Q) score
Zeitfenster: Baseline, 3, 6, 9, and 12 months.

Change in freezing of gait assessed using the Freezing of Gait Questionnaire (FOG-Q). The questionnaire consists of six items, each scored from 0 to 4. The total score ranges from 0 to 24, with higher scores indicating more severe freezing of gait.

Unit of Measure: Points on a scale.

Baseline, 3, 6, 9, and 12 months.
Change in Mini-Mental State Examination (MMSE) score
Zeitfenster: Baseline and 12 months

Change in global cognitive performance assessed using the Mini-Mental State Examination (MMSE). The MMSE assesses orientation, registration, attention and calculation, recall, language, and visuoconstructive abilities. The total score ranges from 0 to 30 points, with higher scores indicating better global cognitive performance.

Unit of Measure: Points on a scale.

Baseline and 12 months
Change in Executive Clock Drawing Task (CLOX1) score
Zeitfenster: Baseline and 12 months

Change in executive function assessed using the CLOX1 component of the Executive Clock Drawing Task. CLOX1 requires the participant to draw a clock independently and primarily assesses executive control. The score ranges from 0 to 15 points, with higher scores indicating better performance and lower scores indicating greater impairment.

Unit of Measure: Points on a scale.

Baseline and 12 months
Change in Executive Clock Drawing Task (CLOX2) score
Zeitfenster: Baseline and 12 months

Change in visuospatial and visuoconstructive performance assessed using the CLOX2 component of the Executive Clock Drawing Task. CLOX2 requires the participant to copy a clock drawn by the examiner. The score ranges from 0 to 15 points, with higher scores indicating better visuospatial and visuoconstructive performance.

Unit of Measure: Points on a scale.

Baseline and 12 months
Change in Tower of London (ToL) score
Zeitfenster: Baseline and 12 months

Change in executive planning and problem-solving performance assessed using the Tower of London (ToL) task. The test assesses planning ability, problem solving, and executive control. The scoring range depends on the specific version and scoring system of the Tower of London used in the study. Higher scores generally indicate better planning performance when the outcome is the number of correctly solved problems, whereas measures such as number of moves, errors, or completion time have the opposite interpretation.

Unit of Measure: Points on a scale.

Baseline and 12 months
Change in Benton Judgment of Line Orientation (Benton JLO) score
Zeitfenster: Baseline and 12 months

Change in visuospatial perception assessed using the Benton Judgment of Line Orientation test. The test evaluates the ability to identify and match the angular orientation of lines. For the standard 30-item version, the raw score ranges from 0 to 30 points, with higher scores indicating better visuospatial perception.

Unit of Measure: Points on a scale.

Baseline and 12 months
Change in Addenbrooke's Cognitive Examination III (ACE-III) score
Zeitfenster: Baseline and 12 months

Change in global cognitive performance assessed using the Addenbrooke's Cognitive Examination III (ACE-III). The ACE-III assesses five cognitive domains: attention, memory, verbal fluency, language, and visuospatial abilities. The total score ranges from 0 to 100 points, with higher scores indicating better cognitive performance.

Unit of Measure: Points on a scale.

Baseline and 12 months
Change in Wechsler Adult Intelligence Scale (WAIS) score
Zeitfenster: Baseline and 12 months

Change in cognitive performance assessed using the Wechsler Adult Intelligence Scale (WAIS). The WAIS assesses multiple domains of cognitive functioning, including verbal comprehension, perceptual reasoning, working memory, and processing speed. Higher standardized scores indicate better cognitive performance.

Unit of Measure: Standardized score.

Baseline and 12 months
Change in Rey Auditory Verbal Learning Test (AVLT) score - Total Learning Score
Zeitfenster: Baseline and 12 months

Change in verbal learning performance assessed using the Rey Auditory Verbal Learning Test (AVLT). A list of 15 words is presented over five learning trials. The total learning score is calculated as the sum of correctly recalled words across Trials I-V and ranges from 0 to 75 words , with higher scores indicating better verbal learning performance.

Unit of Measure: Number of correctly recalled words.

Baseline and 12 months
Change in Rey Auditory Verbal Learning Test (AVLT) score - Delayed Recall
Zeitfenster: Baseline and 12 months

Change in delayed verbal memory assessed using the delayed recall component of the AVLT. After a delay, participants are asked to recall the original 15-word list. The score ranges from 0 to 15 correctly recalled words , with higher scores indicating better delayed verbal memory.

Unit of Measure: Number of correctly recalled words.

Baseline and 12 months
Change in Boston Naming Test (BNT) score
Zeitfenster: Baseline and 12 months

Change in confrontation naming ability assessed using the Boston Naming Test (BNT). In the standard 60-item version, participants are asked to name pictured objects. The total score ranges from 0 to 60 correctly named items, with higher scores indicating better naming and language performance.

Unit of Measure: Number of correctly named items.

Baseline and 12 months
Change in Beck Depression Inventory (BDI) score
Zeitfenster: Baseline and 12 months

Change in severity of depressive symptoms assessed using the Beck Depression Inventory. The total score ranges from 0 to 63 points, with higher scores indicating greater severity of depressive symptoms.

Unit of Measure: Points on a scale.

Baseline and 12 months
Change in Beck Anxiety Inventory (BAI) score
Zeitfenster: Baseline and 12 months

Change in anxiety symptom severity assessed using the Beck Anxiety Inventory (BAI). The questionnaire consists of 21 items evaluating the severity of anxiety symptoms, including physiological, cognitive, and emotional symptoms. Each item is scored from 0 to 3, resulting in a total score ranging from 0 to 63 points. Higher scores indicate greater anxiety symptom severity.

Unit of Measure: Points on a scale.

Baseline and 12 months

Andere Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Change in metabolic, endocrine and nutritional biomarker concentrations
Zeitfenster: Baseline, 3 and 12 months

Change in metabolic and endocrine biomarker concentrations including insulin, leptin, ghrelin, orexin, neuropeptide Y, glucagon-like peptide-1 (GLP-1), growth hormone, insulin-like growth factor-1 (IGF-1), cortisol, lipid profile, total protein, albumin, vitamin B1, vitamin B6, vitamin B12, homocysteine, and methylmalonic acid.

Baseline, 3 and 12 months
Change in inflammatory biomarkers concentrations
Zeitfenster: Baseline, 3 and 12 months

Change in inflammatory and other blood biomarker concentrations assessed through laboratory analysis of peripheral blood samples. The assessment includes cytokines (IL-1β, IL-6, IL-10, IL-18, NF-κB, TGF-β, TNF-α, and RANTES), peripheral blood count parameters, C-reactive protein (CRP), calprotectin, and cystatin C.

Baseline, 3 and 12 months
Change in digital motor biomarkers
Zeitfenster: Baseline, 6 and 12 months

Change in motor fluctuations and medication-induced dyskinesias assessed using electronic wearable devices (BioPoint or Myo).

Baseline, 6 and 12 months
Change in Body Weight
Zeitfenster: Baseline, 3 and 12 months

Change in body weight assessed using a weighing scale. Body weight is measured under standardized conditions, with changes reflecting alterations in overall body mass during the study period. Higher values indicate greater body weight.

Unit of Measure: Kilograms (kg).

Baseline, 3 and 12 months
Change in Skinfold Thickness
Zeitfenster: Baseline, 3 and 12 months

Change in subcutaneous fat thickness assessed using skinfold measurements at standardized anatomical sites. Skinfold thickness is measured using skinfold calipers to estimate subcutaneous adipose tissue. Measurements are expressed in millimeters, with higher values indicating greater subcutaneous fat thickness.

Unit of Measure: Millimeters (mm).

Baseline, 3 and 12 months
Change in Body Composition Assessed by Bioelectrical Impedance Analysis
Zeitfenster: Baseline, 3 and 12 months

Change in body composition assessed using multi-frequency bioelectrical impedance analysis (BIA) with the Maltron Bioscan 920-II Multi-frequency Analyser. Body composition parameters are evaluated based on the device measurements.

Baseline, 3 and 12 months
Change in Walking Tandem Test score
Zeitfenster: Baseline and 12 months

Change in dynamic balance and gait coordination assessed using the Walking Tandem Test. The test evaluates the ability to maintain balance and postural stability while walking heel-to-toe along a straight line. Performance is measured by the time required to complete the test, with shorter completion times indicating better dynamic balance, gait coordination, and postural control.

Unit of Measure: Seconds (s).

Baseline and 12 months
Change in Tandem Pivot Test score
Zeitfenster: Baseline and 12 months

Change in dynamic balance and postural control assessed using the Tandem Pivot Test. The test evaluates the ability to maintain balance and postural stability while performing a pivoting movement in a tandem stance position. Performance is assessed based on the ability to complete the movement, with better performance indicating improved dynamic balance, postural control, and coordination.

Unit of Measure: Seconds (s).

Baseline and 12 months
Change in Tandem Stance Test (TST) score
Zeitfenster: Baseline and 12 months

Change in static balance assessed using the Tandem Stance Test (TST). The test evaluates postural stability by measuring the time a participant can maintain a tandem stance, with one foot positioned directly in front of the other. Performance is measured by the duration of maintaining the position, with longer durations indicating better static balance and postural control.

Unit of Measure: Seconds (s).

Baseline and 12 months
Change in TUG Manual Test score
Zeitfenster: Baseline and 12 months

Change in functional mobility and balance during a manual task assessed using the TUG Manual test, performed while carrying a cup. The time required to complete the test is recorded in seconds, with shorter completion times indicating better functional mobility and balance.

Unit of Measure: Seconds (s).

Baseline and 12 months
Change in Timed Up and Go (TUG) Test score
Zeitfenster: Baseline and 12 months

Change in functional mobility and dynamic balance assessed using the Timed Up and Go (TUG) test. The test measures the time required for a participant to stand up from a chair, walk 3 metres, turn around, walk back, and sit down again. The completion time is recorded in seconds, with shorter times indicating better functional mobility and dynamic balance.

Unit of Measure: Seconds (s).

Baseline and 12 months
Change in Levodopa Equivalent Daily Dose (LEDD)
Zeitfenster: Baseline, 3, 6, 9, and 12 months.

Change in the daily levodopa equivalent dose (LEDD), calculated based on the daily doses of antiparkinsonian medications. Lower values indicate a lower daily dopaminergic medication requirement.

Unit of Measure: Milligrams per day (mg/day).

Baseline, 3, 6, 9, and 12 months.
Change in Total Electrical Energy Delivered (TEED)
Zeitfenster: Baseline, 3, 6, 9, and 12 months.

Change in total electrical energy delivered by the deep brain stimulation (DBS) system, calculated based on stimulation parameters. The value reflects the amount of electrical energy delivered during stimulation.

Unit of Measure: Microwatts (µW).

Baseline, 3, 6, 9, and 12 months.

Mitarbeiter und Ermittler

Hier finden Sie Personen und Organisationen, die an dieser Studie beteiligt sind.

Sponsor

Studienaufzeichnungsdaten

Diese Daten verfolgen den Fortschritt der Übermittlung von Studienaufzeichnungen und zusammenfassenden Ergebnissen an ClinicalTrials.gov. Studienaufzeichnungen und gemeldete Ergebnisse werden von der National Library of Medicine (NLM) überprüft, um sicherzustellen, dass sie bestimmten Qualitätskontrollstandards entsprechen, bevor sie auf der öffentlichen Website veröffentlicht werden.

Haupttermine studieren

Studienbeginn (Tatsächlich)

19. März 2025

Primärer Abschluss (Geschätzt)

28. März 2028

Studienabschluss (Geschätzt)

28. März 2029

Studienanmeldedaten

Zuerst eingereicht

24. Juni 2026

Zuerst eingereicht, das die QC-Kriterien erfüllt hat

11. November 2026

Zuerst gepostet (Tatsächlich)

18. November 2026

Studienaufzeichnungsaktualisierungen

Letztes Update gepostet (Tatsächlich)

18. November 2026

Letztes eingereichtes Update, das die QC-Kriterien erfüllt

11. November 2026

Zuletzt verifiziert

1. Juni 2026

Mehr Informationen

Begriffe im Zusammenhang mit dieser Studie

Andere Studien-ID-Nummern

  • KB/28/2025

Plan für individuelle Teilnehmerdaten (IPD)

Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?

NEIN

Arzneimittel- und Geräteinformationen, Studienunterlagen

Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt

Nein

Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt

Nein

Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .